{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:18Z","timestamp":1787022078010,"version":"build-2736575974"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Urgo Medical"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    This study assesses the cost-effectiveness of Technology Lipido-Colloid with Nano Oligo Saccharide Factor (TLC-NOSF) wound dressings versus neutral dressings in the management of diabetic foot ulcers (DFUs) from a French collective perspective. We used a Markov microsimulation cohort model to simulate the DFU monthly progression over the lifetime horizon. Our study employed a mixed method design with model inputs including data from interventional and observational studies, French databases and expert opinion. The demographic characteristics of the simulated population and clinical efficacy were based on the EXPLORER double-blind randomized controlled trial. Health-related quality of life, costs, and resource use inputs were taken from the literature relevant to the French context. The main outcomes included life-years without DFU (LYs\n                    <jats:sub>w\/DFU<\/jats:sub>\n                    ), quality-adjusted life-years (QALYs), amputations, and lifetime costs. To assess the robustness of the results, sensitivity and subgroup analyses based on the wound duration at treatment initiation were performed. Treatment with the TLC-NOSF dressing led to total cost savings per patient of EUR 35,489, associated with gains of 0.50 LY\n                    <jats:sub>w\/DFU<\/jats:sub>\n                    and 0.16 QALY. TLC-NOSF dressings were established as the dominant strategy in the base case and all sensitivity analyses. Furthermore, the model revealed that, for every 100 patients treated with TLC-NOSF dressings, two amputations could be avoided. According to the subgroup analysis results, the sooner the TLC-NOSF treatment was initiated, the better were the outcomes, with the highest benefits for ulcers with a duration of two months or less (+0.65 LY\n                    <jats:sub>w\/DFU<\/jats:sub>\n                    , +0.23 QALY, and cost savings of EUR 55,710). The results from the French perspective are consistent with the ones from the German and British perspectives. TLC-NOSF dressings are cost-saving compared to neutral dressings, leading to an increase in patients\u2019 health benefits and a decrease in the associated treatment costs. These results can thus be used to guide healthcare decisionmakers. The potential savings could represent EUR 3,345 per treated patient per year and even reach EUR 4,771 when TLC-NOSF dressings are used as first line treatment. The EXPLORER trial is registered with ClinicalTrials.gov, number NCT01717183.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0245652","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T17:44:06Z","timestamp":1611337446000},"page":"e0245652","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4666","authenticated-orcid":true,"given":"Franck","family":"Maunoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Oury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-9085","authenticated-orcid":true,"given":"Laetitia","family":"Thomassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Bohbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Explorer Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"pone.0245652.ref001","author":"World Health Organization","year":"2016","journal-title":"Global report on diabetes"},{"key":"pone.0245652.ref002","first-page":"586","article-title":"Pr\u00e9valence du diab\u00e8te trait\u00e9 pharmacologiquement (tous types) en France en 2015","volume":"27\u201328","author":"L Mandereau-Bruno","year":"2017","journal-title":"Disparit\u00e9s territoriales et socio\u00e9conomiques. Bull Epid\u00e9miol Hebd"},{"key":"pone.0245652.ref003","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"DG Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0245652.ref004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00125-006-0491-1","article-title":"High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe: baseline results from the Eurodiale study","volume":"50","author":"L Prompers","year":"2007","journal-title":"Diabetologia"},{"issue":"12","key":"pone.0245652.ref005","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"BA Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"pone.0245652.ref006","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dme.13054","article-title":"Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom","volume":"33","author":"JW Walsh","year":"2016","journal-title":"Diabet Med"},{"key":"pone.0245652.ref007","unstructured":"Caisse Nationale de l\u2019Assurance Maladie des Travailleurs Salari\u00e9s. Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les d\u00e9penses\u2014Propositions de l\u2019Assurance Maladie pour 2017. Rapport au ministre charg\u00e9 de la S\u00e9curit\u00e9 sociale et au Parlement sur l\u2019\u00e9volution des charges et des produits de l\u2019Assurance Maladie au titre de 2017 (loi du 13 ao\u00fbt 2004); 7 July 2016. French [cited 2017 Jun 7]. Available from: https:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/cnamts_rapport_charges_produits_2017.pdf."},{"key":"pone.0245652.ref008","volume-title":"Piffaretti C Le poids du diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique","author":"S Fosse-Edorh","year":"2018"},{"key":"pone.0245652.ref009","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12968\/jowc.2016.25.5.277","article-title":"Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence","volume":"25","author":"JL Lazaro","year":"2016","journal-title":"J Wound Care"},{"key":"pone.0245652.ref010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2042018813489719","article-title":"Improving major amputation rates in the multicomplex diabetic foot patient: focus on the severity of peripheral arterial disease","volume":"4","author":"A Brechow","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"pone.0245652.ref011","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/193229681100500636","article-title":"Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not","volume":"5","author":"DG Armstrong","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"pone.0245652.ref012","volume-title":"Supporting evidence-based practice: a clinical review of TLC healing matrix","author":"R White","year":"2015","edition":"2"},{"key":"pone.0245652.ref013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-475X.2012.00797.x","article-title":"A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers","volume":"20","author":"S Meaume","year":"2012","journal-title":"Wound Repair Regen"},{"issue":"2","key":"pone.0245652.ref014","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1742-481X.2008.00453.x","article-title":"Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial","volume":"5","author":"JL Schmutz","year":"2008","journal-title":"Int Wound J"},{"issue":"3","key":"pone.0245652.ref015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2213-8587(17)30438-2","article-title":"Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicenter, double-blind, randomised, controlled trial","volume":"6","author":"M Edmonds","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Sup2","key":"pone.0245652.ref016","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/jowc.2017.26.Sup2.S4","article-title":"The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings","volume":"26","author":"KC M\u00fcnter","year":"2017","journal-title":"J Wound Care"},{"issue":"6","key":"pone.0245652.ref017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.12968\/jowc.2019.28.6.358","article-title":"Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer","volume":"28","author":"JL L\u00e1zaro-Mart\u00ednez","year":"2019","journal-title":"J Wound Care"},{"issue":"Suppl 1","key":"pone.0245652.ref018","doi-asserted-by":"crossref","first-page":"e3284","DOI":"10.1002\/dmrr.3284","article-title":"Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review","volume":"36","author":"P Vas","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"pone.0245652.ref019","first-page":"e3283","article-title":"Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update)","volume":"36","author":"International Working Group on the Diabetic Foot (IWGDF)","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"pone.0245652.ref020","article-title":"Medical technologies guidance [MTG42]","author":"National Institute for Health and Care Excellence","year":"2019","journal-title":"UrgoStart for treating diabetic foot ulcers and leg ulcers"},{"issue":"12","key":"pone.0245652.ref021","doi-asserted-by":"crossref","first-page":"808","DOI":"10.12968\/jowc.2019.28.12.808","article-title":"Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers","volume":"28","author":"R Lobmann","year":"2019","journal-title":"J Wound Care"},{"issue":"10","key":"pone.0245652.ref022","doi-asserted-by":"crossref","DOI":"10.12968\/jowc.2020.29.10.543","article-title":"Impact of wound duration on diabetic foot ulcer healing: evaluation of a new sucrose octasulfate wound dressing","volume":"29","author":"R Lobmann","year":"2020","journal-title":"J Wound Care"},{"issue":"2","key":"pone.0245652.ref023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12968\/jowc.2008.17.2.28181","article-title":"An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers","volume":"17","author":"S Flack","year":"2008","journal-title":"J Wound Care"},{"key":"pone.0245652.ref024","author":"French National Authority for Health (HAS)","year":"2020","journal-title":"Choices in methods for economic evaluation"},{"key":"pone.0245652.ref025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"D Husereau","year":"2013","journal-title":"Value Health"},{"key":"pone.0245652.ref026","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"FA Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"pone.0245652.ref027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.12968\/jowc.2013.22.2.78","article-title":"The Explorer study: the first double-blind RCT to assess the efficacy of TLC-NOSF on DFUs","volume":"22","author":"DR Shanahan","year":"2013","journal-title":"J Wound Care"},{"issue":"1","key":"pone.0245652.ref028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1742-481X.2010.00739.x","article-title":"Economic evaluation of Vacuum Assisted Closure Therapy for the treatment of diabetic foot ulcers in France","volume":"8","author":"SJ Whitehead","year":"2011","journal-title":"Int Wound J"},{"issue":"2","key":"pone.0245652.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12968\/jowc.2002.11.2.26675","article-title":"Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries","volume":"11","author":"O Ghatnekar","year":"2002","journal-title":"J Wound CareFeb"},{"key":"pone.0245652.ref030","unstructured":"Institut National de la Statistique et des Etudes Economiques (INSEE). Tableau 68\u2014Table de mortalit\u00e9 des ann\u00e9es 2012\u20132014, donn\u00e9es provisoires arr\u00eat\u00e9es \u00e0 fin d\u00e9cembre 2015 [cited 2017 Dec 21]. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/2851503?sommaire=2851587."},{"key":"pone.0245652.ref031","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","article-title":"Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments","volume":"30","author":"WK Redekop","year":"2004","journal-title":"Diabetes Metab"},{"key":"pone.0245652.ref032","article-title":"Enqu\u00eate t\u00e9l\u00e9phonique aupr\u00e8s d\u2019infirmi\u00e8res hospitali\u00e8res et lib\u00e9rales en charge du traitement des plaies de personnes diab\u00e9tiques (internal report)","author":"Cemka Eval","year":"2011"},{"key":"pone.0245652.ref033","volume-title":"Income and Expenditure Report for 2017. Rapport Charges et Produits de l\u2019Assurance Maladie pour 2017","author":"French Health Insurance (CNAMTS)","year":"2017"},{"key":"pone.0245652.ref034","unstructured":"Ameli. Assurance Maladie en ligne. Liste des Produits et Prestations Remboursables [database on the Internet]; 2019 [cited 2019 Oct 9]. Available from: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/remuneration\/nomenclatures-codage\/liste-produits-prestations-lpp."},{"key":"pone.0245652.ref035","unstructured":"Ameli. Assurance Maladie en Ligne. Nomenclature g\u00e9n\u00e9rale des actes professionnels [database on the Internet]; 2019 [cited 2019 Oct 9]. Available from: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/remuneration\/nomenclatures-codage\/ngap."},{"key":"pone.0245652.ref036"},{"key":"pone.0245652.ref037","unstructured":"Agence Technique de l'Information sur l'Hospitalisation (ATIH). Echelle nationale de co\u00fbts (ENC). [database on the Internet];2019 [cited 2019 Oct 9]. Available from: https:\/\/www.epmsi.atih.sante.fr\/welcomeEpmsi.do."},{"key":"pone.0245652.ref038","unstructured":"Sant\u00e9 publique France [Internet];2019 [cited 2019 May 20]. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/diabete\/documents\/rapport-synthese\/etude-entred-2007-2010."},{"key":"pone.0245652.ref039","article-title":"Hospitalization for podiatric complications in people pharmacologically treated for diabetes in France, in 2013","author":"S Fosse-Edorh","year":"2015"},{"issue":"10","key":"pone.0245652.ref040","doi-asserted-by":"crossref","DOI":"10.12968\/jowc.2020.29.10.543","article-title":"Impact of wound duration on diabetic foot ulcer healing: evaluation of a new sucrose octasulfate wound dressing","volume":"29","author":"R Lobmann","year":"2020","journal-title":"J Wound Care"},{"issue":"2","key":"pone.0245652.ref041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.12968\/jowc.2020.29.2.102","article-title":"Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review","volume":"29","author":"J Dissemond","year":"2020","journal-title":"J Wound Care"},{"issue":"12","key":"pone.0245652.ref042","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.ASW.0000323589.27605.71","article-title":"An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers","volume":"21","author":"EJ Dougherty","year":"2008","journal-title":"Adv Skin Wound Care"},{"issue":"2","key":"pone.0245652.ref043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1017\/S0266462308080252","article-title":"Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers","volume":"24","author":"AW Chuck","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"pone.0245652.ref044","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/iwj.12238","article-title":"Cost-effectiveness of treating vascular leg ulcers with UrgoStart and UrgoCell Contact","volume":"13","author":"M Augustin","year":"2016","journal-title":"Int Wound J"},{"key":"pone.0245652.ref045","article-title":"Guide to the Methods of Technology Appraisals","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"pone.0245652.ref046","unstructured":"German National Institute for Quality and Efficiency in Health Care (IQWiG). General Methods for the Assessment of the Relation of Benefits to Costs. Version 1.0; 19\/11\/2009 [cited 2009 Nov 19]. Available from: https:\/\/tools.ispor.org\/PEguidelines\/source\/Germany_AssessmentoftheRelationofBenefitstoCosts_En.pdf."},{"issue":"7","key":"pone.0245652.ref047","first-page":"CD010471","article-title":"Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews","volume":"14","author":"L Wu","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"pone.0245652.ref048","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/dmrr.2246","article-title":"A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes","author":"FL Game","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"pone.0245652.ref049","doi-asserted-by":"crossref","first-page":"164","DOI":"10.12968\/jowc.2019.28.3.164","article-title":"Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials","volume":"28","author":"ML Sigal","year":"2019","journal-title":"J Wound Care"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T18:22:59Z","timestamp":1697653379000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245652"}},"subtitle":[],"editor":[{"given":"Isabelle","family":"Durand-Zaleski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245652","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}